Clinical trials: Leukemia, completed
Osteosarcoma, Ewing's Sarcoma
Informed Consent in Pediatric Cancer Trials
Background: Informed consent is the process by which prospective participants in clinical trials learn about clinical research in order to decide whether they want to enroll in the study.
- Conditions
- Osteosarcoma, Ewing's Sarcoma, Neuroblastoma, Brain Tumors
- Trial name
- NCT00923650
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia With 17p Deletion, Small Lymphocytic Lymphoma With 17p Deletion
A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion
- Trial name
- NCT01744691
- Testing
- Ibrutinib
- Where
- 55 sites in United States, Australia and 7 more
- Volunteers
- 145 people
- Sponsor
- Pharmacyclics LLC.
Acute Lymphoblastic Leukemia
Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
The primary objective of this phase 1b study is to evaluate the safety and tolerability of blinatumomab and AMG 404 in combination in adults with R/R B-ALL and to estimate the maximum tolerated dose (MTD) and recommended phase 2…
- Trial name
- NCT04524455
- Testing
- Blinatumomab, AMG 404, Dexamethasone Premedication
- Where
- 19 sites in United States, Australia and 7 more
- Volunteers
- 17 people
- Sponsor
- Amgen
COVID-19 Vaccines, Telemedicine
Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool
This study will determine the effectiveness of a vaccine communication mobile health app on parental decisions to vaccinate their children against coronavirus disease 2019 (COVID-19).
- Conditions
- COVID-19 Vaccines, Telemedicine, Vaccine Hesitancy, Pediatric ALL
- Trial name
- MoVeUP (NCT05386355)
- Testing
- COVID-19 Vaccine Uptake App, General Health App
- Where
- 15 sites in United States
- Volunteers
- 1,934 people, healthy volunteers welcome
- Sponsor
- IDeA States Pediatric Clinical Trials Network
Aplastic Anemia, Leukemia, Myeloid, Acute
King's Invasive Aspergillosis Study II
Invasive fungal disease (IFD) is an important cause of mortality and morbidity in patients undergoing intensive chemotherapy or transplantation.
- Conditions
- Aplastic Anemia, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Bone Marrow Transplantation
- Trial name
- NCT02875743
- Testing
- Posaconazole
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- King's College Hospital NHS Trust
Sickle Cell Disease, Solid Tumor
Validating Pain Scales in Children and Young Adults
Background: Assessing pain levels is important to improve treatments for different illnesses. Most pain rating scales are used to determine pain levels in adults. Pain is also a common symptom among children who have cancer.
- Conditions
- Sickle Cell Disease, Solid Tumor, Leukemia, Neurofibromatosis
- Trial name
- NCT01639950
- Where
- United States
- Volunteers
- 252 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myelogenous Leukemia, High-Grade Myelodysplastic Syndrome
A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
This is an open-label, multicenter, phase 2 study of alisertib (MLN8237) in participants with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
- Trial name
- NCT00830518
- Testing
- Alisertib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Wilms Tumor, Neuroblastoma
Pharmacokinetic Study of Doxorubicin in Children With Cancer
Analyze pharmacokinetics of doxorubicin in children with cancer. Furthermore investigate the predictive role of troponin and natriuretic peptides for anthracycline-induced cardiotoxicity .
- Conditions
- Wilms Tumor, Neuroblastoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia
- Trial name
- Doxo (NCT01095926)
- Testing
- doxorubicin
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 101 people
- Sponsor
- University Hospital Muenster
Myelodysplastic Syndromes, Myeloproliferative Disorders
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
Pre-transplant conditioning will include Fludarabine and dose-escalated Busulfan on days -6, -5, -4, and -3. Daily treatment doses will be adjusted to achieve target area under the plasma concentration time curve (AUC).
- Conditions
- Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Myeloma
- Trial name
- NCT00361140
- Testing
- Busulfan, Fludarabine
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Chronic Lymphocytic Leukemia
A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics
This is a Phase 1, Open-Label, Adaptive Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics.
- Trial name
- NCT01841489
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without PSC 833 followed by interleukin-2 or no further therapy in treating older patients who have acute myeloid leukemia.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT00003190
- Testing
- cytarabine, daunorubicin hydrochloride, etoposide
- Where
- United States
- Volunteers
- 640 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia
First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL
The main aim of the present study is to evaluate the clinical efficacy of first-line dasatinib plus conventional chemotherapy for newly diagnosed Ph-positive acute lymphoblastic leukemia.
- Trial name
- ALL (NCT01004497)
- Testing
- Dasatinib, Cyclophosphamide, Vincristine
- Where
- 8 sites in South Korea
- Volunteers
- 51 people
- Sponsor
- The Catholic University of Korea
Di Novo Acute Myeloid Leukemia
Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia
While several studies have been reported with increasing doses of daunorubicin in the first line treatment of Acute Myeloid Leukemia (AML), there is no similar experience with idarubicin as initial treatment of AML.
- Trial name
- NCT01700413
- Testing
- Idarubicin
- Where
- 5 sites in Spain
- Volunteers
- 48 people
- Sponsor
- Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Invasive Fungal Infections
Interest of ß 1-3 D Glucan Assays in Screening for the Onset of Invasive Aspergillosis in Neutropenic Patients With Acute Leukaemia.
In the context of screening for infectious fungal diseases in patients with malignant haemopathy, and particularly patients with acute leukaemia, the investigator aims to evaluate the performance of an already commercialized but…
- Trial name
- BETA GLUCAN (NCT02851680)
- Testing
- blood samples
- Where
- France
- Volunteers
- 476 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Leukemia
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002588
- Testing
- etoposide, topotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Case Comprehensive Cancer Center
Relapsed or Refractory Chronic Lymphocytic Leukemia
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT03739554
- Testing
- CYC065, Venetoclax
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Leukemia, Myeloid, Acute
BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia
The present trial will be performed to determine the MTD and to evaluate the efficacy of BI 2536 in the treatment of elderly patients with relapsed or refractory AML.
- Trial name
- NCT00701766
- Testing
- BI 2536
- Where
- 9 sites in Austria, Germany
- Volunteers
- 71 people
- Sponsor
- Boehringer Ingelheim
Acute Myeloid Leukemia
A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to characterize the regimen limiting toxicities (RLT) and recommended Phase 2 dose (RP2D) of indoximod in patients with newly diagnosed AML receiving remission induction chemotherapy with cytarabine…
- Trial name
- NCT02835729
- Testing
- Idarubicin, Cytarabine, Indoximod Freebase
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- NewLink Genetics Corporation
Leukemia
Studying Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors identify learn more about biomarkers related to cancer.
- Trial name
- NCT01581528
- Testing
- gene expression analysis, cell culture procedure, flow cytometry
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Children's Oncology Group
Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Promyelocytic Leukemia (M3)
Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia
This phase I trial is studying the side effects and best dose of bortezomib in treating young patients with refractory or recurrent leukemia.
- Conditions
- Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Promyelocytic Leukemia (M3), Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
- Trial name
- NCT00077467
- Testing
- bortezomib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)